Dublin, Ohio-based Cardinal Health said it earned $289 million in the second quarter of 2015 as revenue for the major hospital operator jumped more than 15 percent to $25.5 billion.
According to Cardinal, much of the growth came in its pharmaceutical sector, which saw a 16 percent jump in revenue to $22.6 billion. Meanwhile, the company’s medical segment brought in $2.9 billion, 5 percent more than the same period last year.
[Also: Fitch Ratings bullish on for-profit healthcare]
Cardinal’s net operating income, which excluded debt and taxes, was $546 million, up 5 percent year over year.
“Although we experienced some continued challenges in the Canadian market, we saw real progress in most of our business lines and customer channels,” CEO George Barrett said in a statement. “Most important, our organization continues to drive our key strategic priorities with focus on positioning us to create new value for our customers and patients in a time of great change."
The company, which runs hospitals, pharmacies, ambulatory and other outpatient health service centers, also raised its non-diluted earnings guidance to $4.28 to $4.38 per share.
Cardinal said it saw several milestones during the quarter, including its partnership with medical product distributor Henry Schein and a contract manufacturing deal with Bayer HealthCare for the prostate cancer drug, Xofigo.
Twitter: @HenryPowderly